IPCA Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹2,910 crore and net profit of ₹389 crore for the September 2026 quarter.
IPCA Laboratories (NSE: IPCALAB) closed at ₹1,843.80 on 20 Nov 2026, up 28.2% over the past year. Its market capitalisation is ₹46,778 crore and it trades at 32.5 times earnings.
Ipca Laboratories is an integrated pharmaceutical company manufacturing branded and generic formulations, APIs and intermediates. Indian branded formulations are its core profit engine, complemented by formulation exports across Europe, Africa, the Americas, Asia, CIS and Australasia. The consolidated business includes Unichem Laboratories and its US, Brazil, Europe and South Africa operations.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.